Objective Tumor recurrence and metastasis is the most common cause of mortality in
hepatocellular carcinoma (HCC) patients. Despite positive results with vascular endothelial …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest primary
neoplasm. Since HCC is a particularly vascular solid tumor, we determined the antitumor …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Abstract PR-7 Background: Patients (pts) with advanced hepatocellular carcinoma (HCC)
have a poor prognosis. HCC is a highly vascular tumor with increased levels of angiogenic …

4637 Background: Patients (pts) with advanced hepatocellular carcinoma (HCC) have a
poor prognosis. HCC is a highly vascular tumor with increased levels of angiogenic factors …

Sunitinib malate is an oral, multitargeted receptor tyrosine kinase inhibitor of VEGF receptors
1, 2 and 3; PDGF receptors α and β, and other receptor tyrosine kinases implicated in tumor …

4521 Background: HCC is a highly vascular tumor and angiogenic pathways such as VEGF
and IL-6 play a key role in proliferation and angiogenesis. Sunitinib (SU) is an oral …

Objective: To evaluate the safety and efficacy of sunitinib in patients with advanced
hepatocellular carcinoma (HCC) after progression under sorafenib treatment. Methods …

The approval of a multitargeted receptor tyrosine kinase inhibitor, sorafenib, with activity
against vascular endothelial growth factor receptor-2 and-3, Raf-1 and B-Raf, platelet …

Background Hepatocellular carcinoma (HCC) tumour spread is partly dependent on
neoangiogenesis. In this open-label, multicentre, phase II trial done in Europe and Asia …